We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Invalidates Most Of Pfizer Pneumonia Vaccine Patent

Law360 (June 11, 2018, 10:28 PM EDT) -- Following a challenge from Merck Sharp & Dohme Corp., the Patent Trial and Appeal Board said Friday that all but one claim in a patent related to Pfizer Inc.’s top-selling Prevnar 13 pneumonia vaccine were unpatentable as obvious under prior patents.

The vaccine, which earned $5.6 billion in revenue in 2017, is among the world’s best-selling, but the PTAB granted Merck’s request for inter partes review on three separate challenges to one of Pfizer’s Prevnar 13 patents last June. The board said at the time that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.